- Price
- $1,152.13
- Day
- +1.26%
- Mkt Cap
- $1.09T
- 52W Range
- $712.05 – $1,292.65
- Volume
- 1.88M
- Beta
- 0.50
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Eli Lilly dominates the weight loss drug market -- one set to approach $100 billion in a few years. Lilly and rival Novo Nordisk launched weight loss pills this year, and so far, Novo is leading in prescriptions.
Read full article
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read full article
It's impossible to take all the risk out of investing. But that doesn't mean investors can't make a good attempt.
Read full article
There is a correlation between increasing dividends and strong investment performance — even if a stock has a low dividend yield when you buy.
Read full article
Twist Bioscience Corporation (NASDAQ:TWST) on Wednesday announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Co. (NYSE:LLY).
Read full article
Eli Lilly's breakthroughs in its core therapeutic area are driving excellent financial results. The company could hit significant headwinds if it encounters clinical setbacks and ceases to innovate.
Read full article
Shares of Eli Lilly and Company (NYSE:LLY) are trading higher Tuesday morning following positive previews of its late-stage obesity and diabetes pipeline.
Read full article
Eli Lilly's bulls are pointing at a 47% revenue surge and a pipeline loaded with blockbuster candidates, but there are a few uncomfortable details quietly buried in the earnings report that change how the story reads.
Read full article
When it comes to investing, there is no one-size-fits-all approach. Strategies vary based on numerous factors, including but not limited to investors' risk tolerance, net worth, and age.
Read full article
Eli Lilly and Merck both reported second quarter earnings, and the contrast could not be sharper. One company is compounding a franchise that keeps widening, while the other is racing to patch a hole before a patent cliff arrives.
Read full article